Author:
González-Sales Mario,Barrière Olivier,Tremblay Pierre Olivier,Nekka Fahima,Mamputu Jean-Claude,Boudreault Sylvie,Tanguay Mario
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S (2010) Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95:4291–4304
2. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK (2012) Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis 54:1642–1651
3. Theratechnologies Inc. Egrifta® (tesamorelin for injection): US prescribing information [online]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf . Accessed 27 Mar 2015
4. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000ClinPharmR.pdf . Accessed 27 Mar 2015
5. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK (2011) Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab 96:150–158
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献